News
Why Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) is up more than 40% at 11:53 a.m. EDT after the company released positive phase 3 trial data for the Apollo trial testing its RNAi drug patisiran in patients....
What's Next for Alnylam Pharmaceuticals, Inc.?
The past 15 years haven't been easy for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shareholders. The company's new drug candidates are based on science that earned a Nobel Prize in 2006, but....
Why Nabriva Therapeutics Shares Are Falling Today
For the third day in a row Wednesday, shares of Nabriva Therapeutics (NASDAQ: NBRV), a clinical-stage biotech focused on antibiotics, were moving by double-digits. However, today's move is in the....
Why Are Cancer Drugs So Expensive?
All drugs are costly to produce, but cancer drugs are notoriously expensive to push through to market, and every year, treatments get more and more expensive. In this clip from Industry Focus:....
ALPHA MOS : COMMUNIQUE DE MISE A DISPOSITION DE LA NOTE EN REPONSE
OFFRE PUBLIQUE D'ACHAT SIMPLIFIEE
VISANT LES ACTIONS DE LA SOCIETE
ALPHA MOS
INITIEE CONJOINTEMENT PAR
JOLT CAPITAL
AMBROSIA INVESTMENTS
PRESENTEE PAR
ALANTRA
COMMUNIQUE DE MISE....
Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today
After reporting disappointing interim news from its phase 3 study of SPN-810 as a treatment for aggressive impulses in ADHD patients, shares in Supernus Pharmaceuticals (NASDAQ: SUPN) tumbled....
Here's Why Nabriva Therapeutics PLC Is Soaring Today
For the second day in a row, investors in Nabriva Therapeutics (NASDAQ: NBRV) are enjoying double-digit gains. Shares of the clinical-stage biotech are up 15% as of 11:30 a.m. EDT on Tuesday. The....
Here's Why Quidel Corporation Stock Is Popping Today
Shares of Quidel Corporation (NASDAQ: QDEL), a molecular diagnostics specialist with a focus on quick turnarounds, ticked up 9.3% as of 11:26 a.m. EDT on Tuesday in response to a positive....
These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?
These are the best times in a long time for three small biotechs. For two of them, these are the best times ever.Abeona Therapeutics (NASDAQ: ABEO), BeiGene (NASDAQ: BGNE), and Vanda....
Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
The year 2021 -- that's when Gilead Sciences (NASDAQ: GILD) thinks its acquisition of Kite Pharma (NASDAQ: KITE) will start to pay off. When Gilead announced plans to buy Kite, the company stated....
3 High-Yield Pharmaceutical Stocks
It can be tempting to buy stocks based solely on their dividend yield, but that can actually be a big mistake. However, that doesn't mean that all high-yield stocks should be avoided.So which big....
Why Bellicum Pharmaceuticals Stock Is Rising Today
Bellicum Pharmaceuticals (NASDAQ: BLCM), a clinical-stage biotech, saw its shares rise in excess of 11% today on almost three times the normal volume. The adoptive cell therapy company's stock....
What's Behind Progenics Pharmaceuticals, Inc.'s Bump Today?
Shares of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a small-cap biotech with a several irons in the fire, are on the rise today. Despite a lack of significant news, the stock tacked on a....
Why Nabriva Therapeutics PLC Is Skyrocketing
Investors in Nabriva Therapeutics (NASDAQ: NBRV) are having a wonderful start to the trading week. Shares of the clinical-stage biotech focused on antibiotics rose 36% as of 11:30 a.m. EDT on....
3 Value Stocks for Smart Investors
Value investors know that getting a good stock at a good price can be difficult, particularly in markets like we face to day, but it's always worth it when you find one. They tend to offer the....
3 High-Yield Healthcare Stocks
One downside to a long-lasting bull market is that the market's dividend yield declines. That's a big problem for retirees who rely on their portfolio to meet their income needs.Even in today's....
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
There is perhaps no scarier word in the English language than "cancer." More than 15.5 million Americans who were alive as of Jan. 1, 2016, have had cancer at some point in their lives, according....
Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?
Billionaire George Soros is an iconic figure in the world of investing because of his unique ability to consistently beat the broader markets. As such, the quarterly 13F filings of his namesake....
5 Marijuana Stocks Overflowing With Cash
Marijuana may be illegal at the federal level, but that hasn't slowed growth of the drug one iota within the U.S. or North America. In June, Mexico fully legalized medical cannabis, and right now....
3 Stocks to Hold for the Next Century
"Buy and hold" sounds like a simple investing strategy, but it only works if you're confident in your stocks for the very long haul. Titans topple all the time, and truly secular investments are....
Jeff Sessions May Soon Have a Green Light to Wage War on Medical-Marijuana Businesses
The U.S. marijuana industry has witnessed a number of major changes over the past two-plus decades. Since 1996, when California became the first state to legalize medical cannabis for....
Don't Make This Huge Mistake With Celgene
Several years ago, I started to look seriously at investing in Celgene (NASDAQ: CELG) stock. Someone I knew told me that I probably shouldn't get too excited about the biotech. I'm glad I didn't....
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Johnson & Johnson (NYSE: JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings during the period.....
Loxo Oncology's Up 230% in the Past Year -- Can You Still Make Money Buying It?
Loxo Oncology (NASDAQ: LOXO) is one of biotech's best-performing stars this past year, and shares could still have room to run higher if the FDA cooperates with an OK for its lead drug,....
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
You can call them "frenemies." Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) are friends when it comes to blockbuster blood thinner Eliquis. But the two big pharma companies are enemies....